Obinutuzumab treatment for antineutrophil cytoplasmic antibody-associated vasculitis [PDF]
Frontiers in ImmunologyBackgroundAnti-CD20 therapy with rituximab serves as the cornerstone of both induction and maintenance treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Chen Ye +26 more
doaj +2 more sources
Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy [PDF]
Kidney International ReportsIntroduction: B-cell lymphocytes have been demonstrated to play a key role in the pathogenesis underlying membranous nephropathy (MN). The aim of this study was to evaluate the therapeutic efficacy and safety of Obinutuzumab, a glycoengineered type II ...
Xi Qiao
exaly +4 more sources
Obinutuzumab alone may be an effective option for adult minimal change disease: a single-center retrospective observational study [PDF]
BMC NephrologyBackground Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody with more potent and sustained B-cell depletion than rituximab.
Qiong Bai +3 more
doaj +2 more sources
Obinutuzumab versus rituximab in refractory membranous nephropathy: a single-center retrospective cohort study [PDF]
BMC NephrologyBackground Refractory membranous nephropathy (MN) remains challenging. We aim to compare the efficacy and safety of obinutuzumab versus rituximab in adults with refractory or relapsing MN, using a retrospective, single-center study design.
Wenhui Lei +4 more
doaj +2 more sources
Obinutuzumab for refractory minimal change disease in obese patients: a case series [PDF]
Frontiers in MedicineMinimal change disease (MCD) is a common cause of nephrotic syndrome in adults. Rituximab, a type I anti-CD20 antibody, is effective in many cases, but up to 40% of patients show an insufficient or transient response.
Dandan Xue +4 more
doaj +2 more sources
B-Cell Depletion in Glomerular Diseases: Not Always as Safe as We May Think [PDF]
Kidney MedicineB-cell depletion with the chimeric anti-CD20 monoclonal antibody rituximab has revolutionized the treatment of glomerular diseases. Obinutuzumab, a type II glycoengineered anti-CD20 humanized monoclonal antibody, is increasingly being employed as an ...
Decimo Silvio Chiarenza +8 more
doaj +2 more sources
Oncology and TherapyThrombocytopenia has been reported more frequently with obinutuzumab in clinical trials where it was directly compared with rituximab. However, more significant than the frequency, a unique form of severe thrombocytopenia manifesting very early after the
Selin Küçükyurt +2 more
exaly +2 more sources
Obinutuzumab-induced acute thrombocytopenia and leukopenia in ANCA-associated glomerulonephritis: case report and literature review [PDF]
Frontiers in ImmunologyObinutuzumab is a humanized type II anti-CD20 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity. It is widely used in B-cell malignancies and is increasingly being explored in autoimmune diseases such as lupus nephritis. The main
Yiming Jin, Yiqi Huang, Xiaomiao He
doaj +2 more sources
Kidney International ReportsIntroduction: Although rituximab has significantly improved outcomes for patients with membranous nephropathy, response to treatment is not universal and drug resistance can occur.
Harbir Kohli +2 more
exaly +3 more sources
Efficacy and safety of obinutuzumab as rescue therapy for rituximab-resistant and rituximab-recurrent primary membranous nephropathy: a retrospective cohort study [PDF]
Open MedicineWith the recognition of membranous nephropathy as an autoimmune disease, targeting B-cells has emerged as an effective therapeutic agent for primary membranous nephropathy (PMN).
Tian Li +7 more
doaj +2 more sources